Boiron strengthens its medical cannabis strategy with Panaxia Malta

The French group Boiron announced the signing of a strategic partnership with Panaxia Malta, a company specializing in the research and development of therapeutic cannabis-based medications.

This agreement builds on a collaboration that is already underway as part of the French pilot program led by the’French National Agency for the Safety of Medicines and Health Products (ANSM). A pilot program that enabled Boiron to distribute Panaxia products to patients enrolled in the national program.

An option to acquire a majority stake starting in 2029

The core of the agreement rests on a strategic decision: starting in 2029, Boiron will be able to exercise an option to acquire a majority stake in the capital of Panaxia Malta, the European operating subsidiary of Panaxia Pharmaceutical Industries.

This option is granted in exchange for a payment of up to 3.2 million euros. It is therefore not an immediate acquisition, but rather a phased process that allows the French laboratory to secure a potentially dominant position in the Maltese company over the medium term.

For Panaxia Malta, this agreement provides financial and industrial leverage. The stated goal is to continue expanding in European countries where the medical marijuana is authorized to do so, drawing on the regulatory and logistical expertise of its French partner.

The French pilot program as an operational foundation

This connection didn't come out of nowhere. The The two companies have already worked together during the French experiment on the medical marijuana, launched to assess the relevance and feasibility of a supervised rollout in France.

In this context, Boiron was responsible for distributing the drugs developed by Panaxia Malta. This operational collaboration is described as successful, having enabled the French laboratory to gain practical experience in a pharmaceutical sector that is still taking shape.

In this context, the strategy of Boiron appears to be a proactive move into an emerging therapeutic field, which it is also testing CBD products sold in pharmacies. Historically known for homeopathic remedies, the company is diversifying its portfolio by moving into a pharmaceutical segment based on strict regulatory standards and structured clinical research.